GSK 2849466
Alternative Names: GSK2849466Latest Information Update: 28 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Selective androgen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cachexia; Heart failure
Most Recent Events
- 23 Jun 2014 Adverse events and pharmacokinetics data from a phase I trial in Healthy volunteers presented at the Joint Meeting of the 16th International Congress of Endocrinology and the 96th Annual Meeting of the Endocrine Society (ICE/ENDO-2014)
- 01 Feb 2014 Discontinued - Phase-I for Cachexia (In volunteers) in USA (PO) (GlaxoSmithKline pipeline, February 2014)
- 01 Feb 2014 Discontinued - Phase-I for Heart failure in USA (PO) (GlaxoSmithKline pipeline, February 2014)